Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk.

Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk

Gilead Sciences Inc said an analysis showed its antiviral remdesivir helped reduce the risk of death.

Gilead Sciences Inc <GILD.O> said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.

Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate US government trial. That study showed a trend toward better survival for remdesivir but the difference was not statistically significant.

In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity.

Gilead's late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalized patients. The study did not have a placebo comparison.

Dr. Susan Olender from Columbia University Irving Medical Center said in the Gilead statement that the analysis draws from a real-world setting and serves as an important adjunct to clinical trial data even as it is not as vigorous as a randomized controlled trial.

However, Dr. Walid Gellad, a professor at University of Pittsburgh's medical school, called it "a joke" to compare clinical trial data with observational data and conclude anything definitive about mortality.

"The mortality in the remdesivir trials has generally been lower for both control and intervention groups than other trials and other real world cohorts I've seen," Gellad said in an email.

"The real world patients are taken care of at different hospitals than those in the trial and potentially different adjunct treatments. They're different."

Findings from the analysis showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.

The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.

The U.S. government trial in April showed that patients given remdesivir recovered 31% faster than those given a placebo.

Gilead's shares rose 2% to $76.27 in afternoon trading.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Comments

Related news

Pak Court Indicts Ex-President Asif Ali Zardari, 9 Others In Graft Case.

An anti-corruption court in Pakistan on Monday indicted former President Asif Ali Zardari through video link in a graft case where he was accused of influencing authorities to release loans to front...

1 Dead, Several Injured As Explosion Flattens Baltimore Homes: Reports.

A major explosion tore through a Baltimore neighborhood on Monday, leveling several houses, trapping at least five people and critically injuring three, firefighters said.

Lebanon’s cabinet resigns as tensions grow over Beirut explosion.

The decision came after two days of demonstrations over the weekend that saw clashes with security forces firing tear gas at protesters.

Lebanon PM To Announce Government Resignation Over Beirut Blast: Minister.

Lebanese Prime Minister Hassan Diab will announce his government's resignation imminently over the backlash from the deadly Beirut port explosion, a minister told AFP Monday.

1 5

Hot August in Belarus: Ukraine's focus

The latest dramatic developments unfolding in Ukraine's neighboring country Belarus have clearly shown that the August 9 presidential election cannot be referred to as those held in line with the established...

By continuing to browse World News (UAZMI), you acknowledge that you have read the Terms of Use and agree to the use of cookies